Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 113

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 113
---
 these sequencers. Any disruption in Illumina’s operations could impact our supply chain and laboratory operations as well as our ability to conduct our tests, and it could take a substantial amount of time to integrate replacement equipment into our laboratory operations. We believe that there are only a few other manufacturers that are currently capable of supplying and servicing the equipment necessary for our laboratory operations, including sequencers and various associated reagents. The use of equipment or materials provided by these replacement suppliers would require us to alter our laboratory operations which may have an impact in the accuracy of our genetic test results. We will have to depend on these other parties to perform effectively on a timely basis and to comply with regulatory requirements. Transitioning to a new supplier would be time consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate our tests. We cannot assure you that we will be able to secure alternative equipment, reagents and other materials, and bring such equipment, reagents and materials online and revalidate them without experiencing interruptions in our workflow. In the case of an alternative supplier for Illumina, we cannot assure you that replacement sequencers and associated reagents will be available or will meet our quality control and performance requirements for our laboratory operations. If we encounter delays or difficulties in securing, reconfiguring or revalidating the equipment and reagents we require for our tests, our business, financial condition, results of operations and reputation could be adversely affected. Our research and development efforts will be hindered if we are not able to obtain samples, enter into contracts with third parties for access to samples, or complete timely enrollment in future clinical studies, or if defects are discovered in our products. Access to human sample types, such as blood, tissue, saliva and stool is necessary for our research and product development. One of our current sources of human samples for research and product development is through clinical validation protocols, where samples are collected specifically for research purposes under appropriate ethical approvals. These protocols are reviewed and approved by an Ethics Committee in Argentina, in accordance with country -specificlaws and regulations. Additionally, during routine clinical testing, patients have the option to provide informed consent at the time of sample collection. This consent permits the use of their anonymized genomic data for future research purposes, ensuring compliance with privacy and ethical standards. For our consumer wellness and preventive health solutions, customers consent to terms and conditions at the time of purchase that specify anonymized data may be used for research purposes. This approach allows us to